share_log

Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement With Takeda to Discover Molecular Glue Degraders

Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement With Takeda to Discover Molecular Glue Degraders

Degron Therapeutics宣布与武田签署多靶点合作和独家许可协议,以发现分子胶降解剂
PR Newswire ·  05/23 17:30

Collaboration will leverage Degron's GlueXplorer platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation

合作将利用 Degron 的 GluExplorer 发现新型分子胶降解剂的平台 肿瘤学、神经科学和炎症领域的多个靶标

Degron will receive upfront payment and potential milestone payments of up to $1.2 billion

Degron 将获得高达 12 亿美元的预付款和潜在的里程碑式付款

Takeda to make equity investment in the company

武田将对该公司进行股权投资

SAN DIEGO, Calif. and SHANGHAI, China, May 23, 2024 /PRNewswire/ -- Degron Therapeutics ("Degron"), the company using its molecular glue-based targeted protein degradation drug-discovery platform to advance human health, today announced it has entered into a collaboration and exclusive license agreement with Takeda to discover and develop novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation.

加利福尼亚州圣地亚哥和中国上海,2024年5月23日 /PRNewswire/ — Degron Therapeutics(“Degron”)使用其基于分子胶的靶向蛋白降解药物发现平台来促进人类健康,今天宣布已与武田签订合作和独家许可协议,以发现和开发用于肿瘤、神经科学和炎症多个靶标的新型分子胶降解剂。

Degron and Takeda will collaborate to utilize Degron's GlueXplorer platform to identify, validate, and optimize molecular glue degraders for specific therapeutic targets selected by Takeda. Upon reaching a certain stage of advancement, the projects would be transitioned to Takeda for further development and commercialization.

Degron 和武田将合作使用 Degron 的 GluExplorer 该平台用于识别、验证和优化武田选择的特定治疗靶标的分子胶降解剂。在达到一定进展阶段后,这些项目将过渡到武田进行进一步开发和商业化。

"We are excited to collaborate with Takeda, expanding the use of our platform into new therapeutic areas," said Lily Zou, Ph.D., co-founder and CEO of Degron Therapeutics. "Degron's differentiated and powerful GlueXplorer platform has been validated by its robust, first-in-class pipeline of novel molecular glue drugs for disease targets that are undruggable by other modalities or better addressed with this new modality. By partnering with Takeda, we combine our molecular glue discovery expertise with Takeda's vast drug development and commercialization experience in hopes of offering patients worldwide a new class of treatments."

Degron Therapeutics联合创始人兼首席执行官Lily Zou博士表示:“我们很高兴能与武田合作,将我们平台的使用扩展到新的治疗领域。”“Degron差异化且强大的GluExplorer平台已通过其强大的、同类首创的新型分子胶合药物管道得到验证,这些药物用于其他模式无法药物治疗或这种新模式更能解决的疾病靶标。通过与武田合作,我们将分子胶水发现专业知识与武田丰富的药物开发和商业化经验相结合,希望为全球患者提供全新的治疗方案。”

Under the terms of the agreement, Degron Therapeutics will receive an upfront payment and is eligible to receive potential future preclinical, clinical development and commercial milestone payments that could total $1.2 billion if all related milestones are achieved over the course of the agreement. Degron is also eligible to receive tiered royalty payments on sales of any potential commercialized products. The parties have the option to expand the collaboration to include more targets. Additionally, Takeda will make an equity investment in Degron. Degron Therapeutics will retain full ownership of its pipeline programs.

根据协议条款,Degron Therapeutics将获得预付款,并且有资格获得未来潜在的临床前、临床开发和商业里程碑付款,如果在协议过程中实现所有相关里程碑,总额可能为12亿美元。Degron 还有资格获得销售任何潜在商业化产品的分级特许权使用费。双方可以选择扩大合作范围以包括更多目标。此外,武田将对Degron进行股权投资。Degron Therapeutics将保留其管道项目的全部所有权。

"Molecular glue degraders are a new class of drugs that can be directed at targets previously inaccessible or inadequately modulated by other treatment modalities," said Chris Arendt, Chief Scientific Officer, Head of Research at Takeda. "This collaboration with Degron not only adds an innovative new platform to our drug discovery toolbox, it is also an example of cutting-edge innovation emerging in the exciting China biotech sector."

武田首席科学官兼研究主管克里斯·阿伦特说:“分子胶水降解剂是一类新药物,可以针对以前无法获得或未被其他治疗方式充分调节的靶标。”“与Degron的合作不仅为我们的药物发现工具箱增加了创新的新平台,也是令人兴奋的中国生物技术领域出现的尖端创新的典范。”

Founded in 2021, Degron Therapeutics builds on research from the laboratory of ShanghaiTech University professor and company co-founder Yong Cang, Ph.D. Degron developed a proprietary GlueXplorer platform, which encompasses a unique and expanding library of structurally differentiated molecular glue degraders, multiple complementary screening approaches, and extensive assays to thoroughly validate the molecular glue mechanism for degraders discovered by the platform. Degron has generated a large amount of proprietary data and developed an artificial intelligence (AI) algorithm to predict novel molecular glue targets and accelerate compound discovery. Degron has created more than 60 novel diverse cores and 10,000 compounds for its library and a robust pipeline of programs targeting important disease targets including previously undruggable ones across multiple therapeutic areas.

Degron Therapeutics成立于2021年,建立在上海科技大学教授兼公司联合创始人仓勇博士实验室的研究基础上。Degron开发了专有的GluExplorer平台,该平台包括一个独特且不断扩大的结构差异化分子胶降解剂库、多种互补筛选方法以及旨在彻底验证该平台发现的降解剂分子胶机制的广泛试验。Degron 已经生成了大量的专有数据,并开发了一种人工智能 (AI) 算法来预测新的分子胶靶标并加速化合物的发现。Degron已经为其库创建了60多种新颖的多样化核心和10,000种化合物,并针对重要的疾病靶标包括多个治疗领域以前无法药物治疗的靶点的强大项目管道。

About Degron Therapeutics
Degron Therapeutics uses its molecular glue-based targeted protein degradation drug discovery platform to develop novel medicines and advance human health. The company's unique GlueXplorer platform encompasses a rapidly expanding IP-protected compound library and screening systems to develop a new class of small-molecule medicines that target important disease targets, including those previously undruggable. The company's pipeline comprises a growing number of preclinical programs for oncology, inflammation, metabolic disorders, and rare diseases. For more information, please visit .

关于 Degron Therapeutics
Degron Therapeutics使用其基于分子胶的靶向蛋白质降解药物发现平台来开发新药并促进人类健康。该公司独特的 GluExplorer 该平台包括快速扩展的受知识产权保护的化合物库和筛选系统,用于开发针对重要疾病靶标的新型小分子药物,包括那些以前无法药物治疗的药物。该公司的产品线包括越来越多的肿瘤学、炎症、代谢疾病和罕见疾病的临床前项目。欲了解更多信息,请访问 。

SOURCE Degron Therapeutics

来源 Degron Therapeutics

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发